India's Wockhardt says FDA alert affects potential sales of $100 mln
Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates
Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory partial-onset seizures
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Delphi Medical Systems | 1 | 7 | 600 % |
| vascular robotic system | 1 | 7 | 600 % |
| Vicor | 2 | 12 | 500 % |
| Wockhardt | 1 | 6 | 500 % |
| Zoetis | 3 | 16 | 433 % |
| CGI Pharma | 1 | 5 | 400 % |
| Daiichi Sankyo | 4 | 19 | 375 % |
| Merck Serono | 2 | 9 | 350 % |
| Cytori | 1 | 4 | 300 % |
| Oncolytics | 1 | 4 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Cytori | 4 | 47 | 1075 % |
| Cel-Sci | 1 | 9 | 800 % |
| ConvaTec | 1 | 8 | 700 % |
| Wockhardt | 7 | 54 | 671 % |
| Cytokinetics | 2 | 15 | 650 % |
| Virtual Radiologic | 1 | 7 | 600 % |
| Upsher-Smith | 2 | 13 | 550 % |
| Apricus Biosciences | 3 | 17 | 467 % |
| DJO Global | 2 | 11 | 450 % |
| Debiopharm | 7 | 37 | 429 % |